Christopher de Clinton Conway, Chief Philanthropy Officer and Executive Vice President for Strategic Communications at IBRI, shared on LinkedIn:
“The Search for New Cures Is Broken
An important Guest Essay from Ruxandra Teslo, in today’s The New York Times makes a compelling case: America cannot afford to lose its edge in biotechnology.
Dr. Teslo highlights how Australia has become increasingly attractive for early – stage clinical trials because it can move promising therapies from the laboratory to patients faster, while maintaining strong safety standards and transparency.
That’s why the work of Indiana Biosciences Research Institute (IBRI), University of Sydney, and the Sydney Biomedical Accelerator matters.
By connecting American and Australian researchers, institutions and companies, we are accelerating the path from discovery to application while strengthening America’s scientific competitiveness and health security.
Ruxandra Teslo, (Ruxandra T.) is a biotechnology editor at Works In Progress magazine and a nonresident fellow at the IFP – Institute for Progress.
To read the full essay, visit.”
Other articles featuring Christopher de Clinton Conway on OncoDaily.